Why The Time Has Come for Rhythm Pharmaceuticals to Outperform

Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals (RYTM) is a late-stage biopharmaceutical company with a product pipeline that reflects its focus of developing treatments for rare genetic obesity. The firm’s lead product, setmelanotide, is a melanocortin-4 receptor (MC4R) agonist being developed for severe obesity and hyperphagia associated with rare genetic obesity.

The United States FDA has accepted Rhythm’s . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.